The Realities of GLP-1 Weight Loss Medications
elénzia Nutritional Scientist Godsfavour Oghifo discusses GLP-1 medications and their implications.
By elenzia / April 23rd 2025 / Conversations
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) like Ozempic, Wegovy and Mounjaro mimic a natural hormone that regulates appetite, insulin, and blood sugar, helping people feel full faster and eat less. These drugs have taken the UK by storm. Celebrities rave about them, and social media is flooded with “before and after” transformations. But beneath the hype, a darker reality lurks. While GLP-1 RAs are increasingly used for weight management, emerging data highlight potential risks that warrant closer scrutiny. Current evidence suggests these medications may pose greater challenges than initially anticipated, particularly when used outside approved guidelines.
The Quick Fix Trap
We’ve all been there: scrolling through Instagram, seeing someone’s jaw-dropping weight loss, and wondering, “Is this the answer I’ve been searching for?” But what if the solution to your weight struggles could become a nightmare? These injections aren’t just about shedding pounds—they’re linked to serious health risks that demand attention.
Gastrointestinal Chaos: More Than Just Nausea
The most commonly reported side effects of GLP1-medications are gastrointestinal, including nausea, vomiting, diarrhoea, constipation, and abdominal pain (WebMD, 2024). These symptoms are usually mild to moderate and tend to decrease over time, but in some cases, they can lead to severe dehydration, kidney stones, and even gallbladder disorders which require medical attention (WebMD, 2024). The MHRA has reported a 46% surge in hospitalisations for adverse reactions, including cases where patients collapsed from dehydration or organ stress (MHRA, 2024). Gastrointestinal symptoms like nausea and diarrhoea affect up to 50% of users, with most experiencing mild to moderate episodes that diminish over time (PMC, 2015). Imagine feeling like your body is “at war” with itself—this is the reality for many users. One user on Drugs.com wrote: ”I was nauseous the whole 5 months when I was on it. I had three attacks of non-stop vomiting and the last attack I collapsed 4 times and passed out… it did not agree with me, so I stopped.” This is a grim picture.
Pancreatitis Risk: Understanding the Potential Concerns
Fever, vomiting, and a tender abdomen—these are the hallmarks of pancreatitis, a severe inflammation of the pancreas. According to the MHRA, this condition affects 1 in 100 to 1 in 10,000 users, depending on the medication (MHRA, 2024). While rare, it’s a life-threatening emergency that often requires hospitalization. A pooled analysis of clinical trials found a slightly elevated risk of pancreatitis in GLP-1 injection users compared to other anti-diabetic drugs (PMC, 2015).
Misuse and Dependency
The UK’s ‘quick fix’ culture has led to dangerous habits. Patients ‘microdose’ to indulge in festive feasts, unaware that abrupt changes can spike pancreatitis risk. Others use unregulated online pharmacies, risking counterfeit products or improper dosing. According to the latest data from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA), as of January 31, 2025, there have been 82 deaths linked to adverse reactions associated with GLP-1 RAs in the UK, with many cases involving off-label use for weight loss alone (BMJ 2025)
Long-Term Risks: Beyond the Scale
While GLP-1 RAs curb appetite, they disrupt natural metabolic processes. Studies reveal a 30% higher risk of nausea/vomiting with long-term use (PMC, 2015). But the problem is, we still don’t fully understand their long-term effects. Most trials span just a few years, leaving unanswered questions about decades of use. Could chronic inflammation or metabolic imbalances emerge? Only time—and more research—will tell.
Ozempic Face and Muscle Loss
While these injections work wonders for your waistline, they can wreak havoc on your face. “Ozempic face” is a growing concern: rapid weight loss can leave your face gaunt, hollow, and prematurely aged. As you rapidly shed fat, your skin may not bounce back, leading to sagging, wrinkles, and a sunken appearance. A recent scientific roundtable revealed that participants in clinical trials using GLP-1 agonists lost 10% or more of their muscle mass during the 68–72-week interventions. To put that in perspective, that’s about the same muscle loss you’d expect from 20 years of aging. While the GLP-1 drugs themselves might have some beneficial effects on muscle, the drastic calorie restriction they induce seems to outweigh those benefits, leading to a net loss of precious muscle tissue (Mechanick et al. 2025).
Straining the NHS: A Systemic Problem
The surge in demand has stretched healthcare resources. There have been reports of hospitalisations related to adverse reactions, with more than 500 cases documented in the UK as of early 2025, diverting attention from sustainable obesity solutions (Pharmaceutical Journal 2025). Meanwhile, shortages for diabetes patients highlight ethical concerns about prioritising cosmetic weight loss over critical medical needs.
From Quick Fixes to Long-Term Health
Here’s the harsh truth: weight loss isn’t just about a needle. It’s about holistic health improvement: building healthy habits, nourishing your body, and moving your body. These injections might offer a temporary fix, but they don’t address the underlying issues. Without those fundamental changes, you’re likely to end up right back where you started. Also, before considering pharmaceutical interventions, it’s essential to do your own research, consult with healthcare professionals, and explore all available options. This might involve investigating natural alternatives to GLP-1, like elénzia CONTROL®, focusing on dietary changes, incorporating regular physical activity, and addressing any underlying emotional or psychological factors that contribute to unhealthy habits. By taking a holistic and informed approach, you can pave the way for long-term well-being and avoid the potential pitfalls of relying solely on medications.
The Bottom Line
GLP-1 injections offer short-term results but carry long-term risks that could overwhelm the NHS and harm public health. While they may help some, their widespread misuse and hidden dangers make them a risky gamble. For lasting change, we need to prioritise holistic solutions—not quick fixes.
